Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis

Chinese Medical Journal

Volumn 131, Issue 22, 2018, Pages 2683-2692

  Li, Zhan Guo ^a   Liu, Yi ^b   Xu, Hu Ji ^c   Chen, Zhi Wei ^d   Bao, Chun De ^e   Gu, Jie Ruo ^f   Zhao, Dong Bao ^g   An, Yuan ^a   Hwang, Lie Ju ^h   Wang, Lisy ^h   Kremer, Joel ⁱ   Wu, Qi Zhe ^h  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h PFIZER INC   (United States)

ⁱ ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Clinical Efficacy; Patient Reported Outcomes; Rheumatoid Arthritis; Safety; Tofacitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; TOFACITINIB; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DAS28; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF ARTHRITIS; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; TOOTH PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85056498015     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.245157     Document Type: Review

References (38)

1. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010;28:S32-40.
2. Wang G, Mu R, Xu H. Management of rheumatoid arthritis in People's Republic of China - Focus on tocilizumab and patient considerations. Int J Gen Med 2015;8:187-94. doi: 10.2147/IJGM.S81633.
3. Li Z, Yang Y. Rheumatology in China: Challenges and development. Rheumatology (Oxford) 2012;51:1733-4. doi: 10.1093/rheumatology/ kes166.
4. Zhang X, Mu R, Wang X, Xu C, Duan T, An Y, et al. The impact of rheumatoid arthritis on work capacity in Chinese patients: A cross-sectional study. Rheumatology (Oxford) 2015;54:1478-87. doi: 10.1093/rheumatology/kev014.
5. Xu C, Wang X, Mu R, Yang L, Zhang Y, Han S, et al. Societal costs of rheumatoid arthritis in China: A hospital-based cross-sectional study. Arthritis Care Res (Hoboken) 2014;66:523-31. doi: 10.1002/ acr.22160.
6. Langley PC, Mu R, Wu M, Dong P, Tang B. The impact of rheumatoid arthritis on the burden of disease in urban China. J Med Econ 2011;14:709-19. doi: 10.3111/13696998.2011.611201.
7. Wang GY, Zhang SL, Wang XR, Feng M, Li C, An Y, et al. Remission of rheumatoid arthritis and potential determinants: A national multi-center cross-sectional survey. Clin Rheumatol 2015;34:221-30. doi: 10.1007/s10067-014-2828-3.
8. Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 2015;18:685-713. doi: 10.1111/1756-185X.12754.
9. Singh JA, Saag KG, Bridges SL Jr. Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26. doi: 10.1002/art.39480.
10. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. doi: 10.1136/ard.2009.123919.
11. Li ZG. A new look at rheumatology in China - Opportunities and challenges. Nat Rev Rheumatol 2015;11:313-7. doi: 10.1038/ nrrheum.2014.218.
12. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509. doi: 10.1136/annrheumdis-2013-204573.
13. Li R, Liu X, Ye H, Yao HH, Guo JL, Li GT, et al. Magnetic resonance imaging in early rheumatoid arthritis: A multicenter, prospective study. Clin Rheumatol 2016;35:303-8. doi: 10.1007/s10067-016-3180-6.
14. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care. Clin Ther 2011;33:679-707. doi: 10.1016/j.clinthera.2011.05.044.
15. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: A discrete-choice experiment. Value Health 2013;16:385-93. doi: 10.1016/j.jval.2012.11.007.
16. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29. doi: 10.1002/art.33383.
17. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009;60:1895-905. doi: 10.1002/ art.24567.
18. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81. doi: 10.1002/art.33419.
19. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. et al. Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-8. doi: 10.1002/ acr.20494.
20. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S, et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study. Mod Rheumatol 2015;25:514-21. doi: 10.3109/14397595.2014.995875.
21. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013;381:451-60. doi: 10.1016/ S0140-6736(12)61424-X.
22. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507. doi: 10.1056/NEJMoa1109071.
23. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med 2013;159:253-61. doi: 10.7326/ 0003-4819-159-4-201308200-00006.
24. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86. doi: 10.1056/NEJMoa1310476.
25. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70. doi: 10.1002/art.37816.
26. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19. doi: 10.1056/NEJMoa1112072.
27. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017;390:457-68. doi: 10.1016/S0140-6736(17)31618-5.
28. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837-52. doi: 10.3899/ jrheum.130683.
29. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, long-term extension study. Arthritis Res Ther 2016;18:34. doi: 10.1186/s13075-016-0932-2.
30. Wollenhaupt J, Silverfield J, Lee EB, Terry K, Kwok K, Strengholt S, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. Arthritis Rheumatol 2017;69 (suppl 10):683-4.
31. Li Z, An Y, Su H, Li X, Xu J, Zheng Y, et al. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a phase 3 randomized controlled trial. Int J Rheum Dis 2018;21:402-14. doi: 10.1111/1756-185x.13244.
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. doi: 10.1002/art.1780310302.
33. Strand V, Burmester GR, Zerbini CA, Mebus CA, Zwillich SH, Gruben D, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: Patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken) 2015;67:475-83. doi: 10.1002/acr.22453.
34. Strand V, Kremer J, Wallenstein G, Kanik KS, Connell C, Gruben D, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther 2015;17:307. doi: 10.1186/s13075-015-0825-9.
35. Strand V, van Vollenhoven RF, Lee EB, Fleischmann R, Zwillich SH, Gruben D, et al. Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford) 2016;55:1031-41. doi: 10.1093/ rheumatology/kev442.
36. Pfizer Inc. Tofacitinib Citrate Tablets Labeling Document. China: Pfizer Inc.; 2017.
37. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
38. World Health Organization. Global Tuberculosis Report 2015. Available from: http://www.who.int/tb/publications/global-report/ en/. [Last accessed on 2016 Oct 19].